Endevica Bio: Funding, Investors & Team (Sep 2026)
The leading medication candidate from Endevica Bio is a peptide therapy for the treatment of cachexia brought on by cancer and other chronic illnesses. Phase 1 clinical studies are being conducted in the US.
Endevica Bio has raised $10.0M across 1 funding round on record, the most recent a Series B of $10.0M announced in Jan 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Endevica Bio Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Endevica Bio Funding Rounds
Endevica Bio Founders and Leadership Team
No contact details are on record for this team yet.
Endevica Bio Funding Compared to Other Biotechnology Startups
Endevica Bio's latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Endevica Bio in Biotechnology and Columbia
Companies Similar to Endevica Bio
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Endevica Bio Funding FAQs
What does Endevica Bio do?
The leading medication candidate from Endevica Bio is a peptide therapy for the treatment of cachexia brought on by cancer and other chronic illnesses. Phase 1 clinical studies are being conducted in the US.
How much funding has Endevica Bio raised?
Endevica Bio has raised $10.0M across 1 round on record. The most recent is a Series B of $10.0M announced in Jan 2023.
When did Endevica Bio last raise funding?
Endevica Bio's most recent funding round on record is a Series B of $10.0M, announced in Jan 2023.
Who founded Endevica Bio?
FundedIQ lists Kenneth Gruber (Founder) at Endevica Bio.
Where is Endevica Bio headquartered?
Endevica Bio is based in Columbia, Missouri, United States.
How many employees does Endevica Bio have?
Endevica Bio is in the 1-10 employee band.
How does Endevica Bio's funding compare to other Biotechnology startups?
Endevica Bio's latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Endevica Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Endevica Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.